• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙心血管疾病预防项目的成本效益

Cost-effectiveness of cardiovascular prevention programs in Spain.

作者信息

Plans-Rubió P

机构信息

General Direction of Public Health, Barcelona.

出版信息

Int J Technol Assess Health Care. 1998 Spring;14(2):320-30. doi: 10.1017/s0266462300012289.

DOI:10.1017/s0266462300012289
PMID:9611906
Abstract

Individual programs for prevention of cardiovascular disease include dietary and drug treatment of hypercholesterolemia, hypertension treatment, and smoking cessation therapies. In this study, the cost-effectiveness of available cardiovascular prevention programs was assessed in Spain in terms of net cost per life-year gained (LYG). Cost-effectiveness ratios ranged from US $2,600 to $80,000 per LYG in men and from $4,500 to $230,000 per LYG in women. In men aged 40-59 years, the ranking of increasing cost-effectiveness was: smoking cessation ($2,608-3,738 per LYG); treatment of moderate and severe hypertension ($8,564-38,678 per LYG); treatment of mild hypertension ($11,906-59,840 per LYG); dietary treatment ($16,143-20,158 per LYG); and drug treatment of hypercholesterolemia ($33,850-81,010 per LYG). In women, the ranking list was:smoking cessation ($4,482-5,756 per LYG), treatment of moderate and severe hypertension ($9,585-57,983 per LYG), treatment of mild hypertension ($15,248-86,075 per LYG), dietary treatment ($57,175-62,154 per LYG); and drug treatment of hypercholesterolemia ($104,100-259,150 per LYG).

摘要

心血管疾病的个体预防方案包括高胆固醇血症的饮食和药物治疗、高血压治疗以及戒烟疗法。在本研究中,在西班牙根据每获得一个生命年(LYG)的净成本评估了现有心血管预防方案的成本效益。男性的成本效益比为每LYG 2600美元至80000美元,女性为每LYG 4500美元至230000美元。在40至59岁的男性中,成本效益递增的排序为:戒烟(每LYG 2608 - 3738美元);中度和重度高血压治疗(每LYG 8564 - 38678美元);轻度高血压治疗(每LYG 11906 - 59840美元);饮食治疗(每LYG 16143 - 20158美元);以及高胆固醇血症的药物治疗(每LYG 33850 - 81010美元)。在女性中,排序为:戒烟(每LYG 4482 - 5756美元),中度和重度高血压治疗(每LYG 9585 - 57983美元),轻度高血压治疗(每LYG 15248 - 86075美元),饮食治疗(每LYG 57175 - 62154美元);以及高胆固醇血症的药物治疗(每LYG 104100 - 259150美元)。

相似文献

1
Cost-effectiveness of cardiovascular prevention programs in Spain.西班牙心血管疾病预防项目的成本效益
Int J Technol Assess Health Care. 1998 Spring;14(2):320-30. doi: 10.1017/s0266462300012289.
2
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.他汀类药物在心血管疾病一级预防中的成本效益:比利时的系统评价与经济分析
Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354.
3
[Cost-effectiveness of hypertension treatment in Catalonia (Spain)].[西班牙加泰罗尼亚高血压治疗的成本效益]
Med Clin (Barc). 2002 Feb 23;118(6):211-6. doi: 10.1016/s0025-7753(02)72338-5.
4
Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.降低胆固醇水平、血压及吸烟以预防冠心病的治疗措施的成本效益分析:在西班牙开展的评估性研究
Pharmacoeconomics. 1998 May;13(5 Pt 2):623-43. doi: 10.2165/00019053-199813050-00014.
5
Cost effectiveness of full coverage of the medical management of smoking cessation in France.法国全面覆盖戒烟医疗管理的成本效益。
Tob Control. 2014 May;23(3):223-30. doi: 10.1136/tobaccocontrol-2012-050520. Epub 2012 Nov 29.
6
Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.考虑到吸烟相关疾病的经济负担,法国免费提供戒烟治疗的成本效益
PLoS One. 2016 Feb 24;11(2):e0148750. doi: 10.1371/journal.pone.0148750. eCollection 2016.
7
Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.西班牙高胆固醇血症饮食治疗的成本效益
Public Health. 1997 Jan;111(1):33-40. doi: 10.1038/sj.ph.1900304.
8
Cost-effectiveness of hypertension therapy according to 2014 guidelines.根据2014年指南的高血压治疗成本效益
N Engl J Med. 2015 Jan 29;372(5):447-55. doi: 10.1056/NEJMsa1406751.
9
A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.日本阿司匹林用于心血管疾病一级预防的卫生经济学评价
Intern Med. 2007;46(4):157-62. doi: 10.2169/internalmedicine.46.1843. Epub 2007 Feb 15.
10
Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.高血压和高胆固醇无症状筛查及阿司匹林一级预防咨询的健康益处与成本效益
Ann Fam Med. 2017 Jan;15(1):23-36. doi: 10.1370/afm.2015. Epub 2017 Jan 6.

引用本文的文献

1
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂的成本效用分析与生活质量:一项为期两年的多中心非随机研究
Diseases. 2024 Oct 5;12(10):244. doi: 10.3390/diseases12100244.
2
The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.使用获得的每生命年成本作为西班牙成本效益的衡量标准:对近期出版物的系统回顾。
Eur J Health Econ. 2012 Dec;13(6):723-40. doi: 10.1007/s10198-011-0326-y. Epub 2011 Jun 10.
3
[Proposals for the appropriate organisation of smoking-dependence care and financing its pharmacological treatment].
[关于吸烟依赖护理的适当组织及其药物治疗融资的建议]
Aten Primaria. 2008 Aug;40(8):381-3. doi: 10.1157/13125401.
4
Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.降胆固醇药物的经济学评估:一项批判性的系统综述。
Pharmacoeconomics. 2007;25(3):187-99. doi: 10.2165/00019053-200725030-00002.
5
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.依西美坦、阿那曲唑、来曲唑或他莫昔芬辅助治疗绝经后可手术切除且雌激素受体阳性乳腺癌的药物经济学分析
Clin Transl Oncol. 2006 May;8(5):339-48. doi: 10.1007/s12094-006-0180-z.
6
Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.戒烟方法与洛伐他汀治疗高胆固醇血症之间的资源分配:基于成本效益和社会福利函数
Pharmacoeconomics. 2004;22(1):55-69. doi: 10.2165/00019053-200422010-00005.
7
[Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension].[依那普利与尼群地平联合治疗高血压成本效益分析的理论模型]
Aten Primaria. 2003;31(6):366-71. doi: 10.1016/s0212-6567(03)70700-8.
8
Coverage of smoking cessation treatment by union health and welfare funds.工会健康和福利基金对戒烟治疗的覆盖情况。
Am J Public Health. 2001 Sep;91(9):1412-5. doi: 10.2105/ajph.91.9.1412.